Stakeholder Insight: Acute Stroke

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-04-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Stroke is one of the top three causes of death and incidence is expected to increase in the next ten years. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor. Therefore the opportunity for new drugs is huge and lucrative for companies willing to invest in increasing awareness.


Scope

  • 180 physician interviews carried out across the seven major markets, including Neurologists, ER physicians and Geriatricians
  • Four key opinion leader interviews carried out with stroke specialists
  • Estimated incidence of stroke by country for the seven major markets
  • Detailed treatment trees to show acute stroke patient flows at country level


    • Report Highlights
    Increasing awareness of the symptoms and urgency of stroke are essential for patient outcomes to improve. Datamonitor research highlights that one of the biggest delays in patients receiving treatment is late presentation to hospital, as patients often perceive symptoms as not serious or do not recognize they are having a stroke.

    Stroke units need to have a standard definition across countries and ideally patients should be taken straight to stroke units by Medical Emergency Services. This would greatly improve treatment times as facilities are located conveniently and specialists are at hand to differentiate between stroke types and initiate appropriate treatment.

    Datamonitor research shows that no one pharmacological treatment protocol produces better outcomes than another. However, even with the lack of pharmacological therapies, death rates and recurrence figures are better in Japan, so maybe countries should look to Japan for best practice strategies.


    Reasons to Purchase

  • Target physicians more effectively, through an understanding of current prescribing trends and practice
  • Develop products to meet the key unmet needs in stroke therapeutics - enhanced safety profiles and greater time window for initiation
  • Create physician and patient education programs for existing and future drugs to increase treatment rates and drive drug usage

    • Table of Contents

    Other users found this report page using the following search terms: stroke neuroprotection stroke acute what treatment definition uk headache patient ischemic define

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.